| Literature DB >> 25358465 |
Leila Molaeipoor1, Jalal Poorolajal2, Minoo Mohraz3, Nader Esmailnasab4.
Abstract
OBJECTIVES: The human immunodeficiency virus (HIV) and Mycobacterium tuberculosis co-infection is a major global challenge. It is not clear why some HIV-positive people are co-infected with tuberculosis (TB) while others are not. This study addressed that question.Entities:
Keywords: Acquired immunodeficiency syndrome; Case-control studies; Human immunodeficiency virus; Iran; Risk factors; Tuberculosis
Year: 2014 PMID: 25358465 PMCID: PMC4258718 DOI: 10.4178/epih/e2014024
Source DB: PubMed Journal: Epidemiol Health ISSN: 2092-7193
Results from the bivariate logistic regression analysis of binary and continuous predictors of M. tuberculosis/HIV co-infection using unadjusted odds ratios (ORs)
| Variables | TB cases (HIV+/TB+) | Non-TB cases (HIV+/TB-) | Unadjusted OR (95% CI) | p-value |
|---|---|---|---|---|
| Gender | ||||
| Female | 19 (7.88) | 480 (22.36) | 1.00 | |
| Male | 222 (92.12) | 1,667 (77.64) | 3.36 (2.08-5.43) | 0.001 |
| Age (yr) | ||||
| 18-29 | 47 (19.50) | 636 (29.75) | 1.00 | |
| 30-39 | 111 (46.06) | 956 (44.71) | 1.57 (1.10-2.24) | 0.01 |
| ≥40 | 83 (34.44) | 546 (25.54) | 2.06 (1.41-3.00) | 0.001 |
| Marital status | ||||
| Married | 76 (32.76) | 832 (40.88) | 1.00 | |
| Single | 101 (43.53) | 782 (38.43) | 1.41 (1.03-1.93) | 0.03 |
| Divorced | 44 (18.97) | 315 (15.48) | 1.53 (1.03-2.27) | 0.03 |
| Widowed | 11 (4.74) | 106 (5.21) | 1.14 (0.58-2.21) | 0.71 |
| Educational level | ||||
| High (>12 yr) | 8 (3.72) | 146 (7.97) | 1.00 | |
| Low (≤12 yr) | 207 (96.28) | 1,685 (92.03) | 2.24 (1.08-4.63) | 0.03 |
| Imprisonment | ||||
| No | 48 (19.92) | 839 (39.08) | 1.00 | |
| Yes | 193 (80.08) | 1,308 (60.92) | 2.58 (1.86-3.58) | 0.001 |
| Smoker | ||||
| No | 65 (30.95) | 853 (44.87) | 1.00 | |
| Yes | 145 (69.05) | 1,048 (55.13) | 1.82 (1.34-2.47) | 0.001 |
| Narcotic use | ||||
| No | 80 (33.20) | 1,042 (48.53) | 1.00 | |
| Yes | 161 (66.80) | 1,105 (51.47) | 1.90 (1.43-2.51) | 0.001 |
| Alcohol use | ||||
| No | 221 (93.64) | 2,031 (95.85) | 1.00 | |
| Yes | 15 (6.36) | 88 (4.15) | 1.57 (0.89-2.76) | 0.12 |
| Route of HIV transmission | ||||
| Sexual | 21 (8.71) | 494 (23.01) | 1.00 | |
| Intravenous drug users | 116 (48.13) | 751 (34.98) | 3.63 (2.25-3.86) | 0.001 |
| Transfusion | 5 (2.07) | 66 (3.07) | 1.78 (0.65-4.89) | 0.26 |
| Tattoos | 2 (0.83) | 26 (1.21) | 1.81 (0.40-8.13) | 0.44 |
| Surgery or dentistry | 2 (0.83) | 20 (0.93) | 2.35 (0.52-10.73) | 0.27 |
| Multiple exposure | 87 (36.10) | 680 (31.67) | 3.01 (1.84-4.91) | 0.001 |
| Unknown | 8 (3.32) | 110 (5.12) | 1.71 (0.74-3.96) | 0.21 |
| Sexual route of transmission | ||||
| Spouse | 15 (16.85) | 358 (34.52) | 1.00 | |
| Heterosexual | 68 (76.40) | 597 (57.57) | 2.72 (1.53-4.83) | 0.001 |
| Homosexual | 1 (1.12) | 26 (2.51) | 0.92 (0.12-7.22) | 0.93 |
| Bisexual | 5 ( 5.62) | 56 (5.40) | 2.13 (0.75-6.09) | 0.16 |
| Previous TB infection | ||||
| No | 231 (95.85) | 2,131 (99.25) | 1.00 | |
| Yes | 10 (4.15) | 16 (0.75) | 5.77 (2.59-12.85) | 0.001 |
| Hepatitis C virus | ||||
| No | 111 (46.06) | 1,253 (58.36) | 1.00 | |
| Yes | 130 (53.94) | 894 (41.64) | 1.64 (1.26-2.15) | 0.001 |
| Isoniazid preventive therapy | ||||
| No | 234 (97.10) | 1,811 (84.35) | 1.00 | |
| Yes | 7 (2.90) | 336 (15.65) | 0.16 (0.08-0.35) | 0.001 |
| Antiretroviral therapy | ||||
| No | 1,356 (63.16) | 136 (56.43) | 1.00 | |
| Yes | 791 (36.84) | 105 (43.57) | 1.32 (1.01-1.73) | 0.04 |
| CD4 cell count (cells/mm3) | ||||
| ≥350 | 33 (16.92) | 656 (38.54) | 1.00 | |
| 201-249 | 34 (17.44) | 380 (22.33) | 1.78 (2.66-6.62) | 0.02 |
| 50-200 | 74 (37.95) | 410 (24.09) | 3.59 (2.34-5.51) | 0.001 |
| <50 | 54 (27.69) | 256 (15.04) | 4.19 (2.66-6.61) | 0.001 |
| Trend test for strata of CD4 count | 241 (100.00) | 2,147 (100.00) | 1.64 (1.43-1.88) | 0.001 |
HIV, human immunodeficiency virus;TB, tuberculosis; CI, confidence interval.
HIV+/TB+, human immunodeficiency virus positive patients with Mycobacterium tuberculosis co-infection;
HIV+/TB-, human immunodeficiency virus positive patients without Mycobacterium tuberculosis co-infection.
Results from the multivariate logistic regression analysis of binary and continuous predictors of M. tuberculosis/HIV co-infection using odds ratios (ORs) adjusted for all other variables in the model (pseudo R2=0.144)
| Variables | TB cases (HIV+/TB+) | Non-TB cases (HIV+/TB-) | Adjusted OR (95% CI) | p-value |
|---|---|---|---|---|
| Marital status | ||||
| Married | 76 (32.76) | 832 (40.88) | 1.00 | |
| Single | 101 (43.53) | 782 (38.43) | 0.95 (0.63-1.45) | 0.82 |
| Divorced | 44 (18.97) | 315 (15.48) | 1.09 (0.66-1.81) | 0.74 |
| Widow | 11 (4.74) | 106 (5.21) | 1.57 (0.72-3.39) | 0.25 |
| Educational level | ||||
| High (>12 yr) | 8 (3.72) | 146 (7.97) | 1.00 | |
| Low (≤12 yr) | 207 (96.28) | 1,685 (92.03) | 0.93 (0.43-2.05) | 0.86 |
| Imprisonment | ||||
| No | 48 (19.92) | 839 (39.08) | 1.00 | |
| Yes | 193 (80.08) | 1,308 (60.92) | 3.82 (2.11-6.90) | 0.001 |
| Smoker | ||||
| No | 65 (30.95) | 853 (44.87) | 1.00 | |
| Yes | 145 (69.05) | 1,048 (55.13) | 1.27 (0.77- 2.10) | 0.36 |
| Previous TB infection | ||||
| No | 231 (95.85) | 2,131 (99.25) | 1.00 | |
| Yes | 10 (4.15) | 16 (0.75) | 5.54 (1.99- 15.39) | 0.001 |
| Isoniazid preventive therapy | ||||
| No | 234 (97.10) | 1,811 (84.35) | 1.00 | |
| Yes | 7 (2.90) | 336 (15.65) | 0.13 (0.06-0.31) | 0.001 |
| Antiretroviral therapy | ||||
| No | 1,356 (63.16) | 136 (56.43) | 1.00 | |
| Yes | 791 (36.84) | 105 (43.57) | 1.81 (1.26-2.61) | 0.001 |
| CD4 cell count (cells/mm3) | ||||
| ≥350 | 33 (16.92) | 656 (38.54) | 1.00 | |
| 201-249 | 34 (17.44) | 380 (22.33) | 2.15 (1.25-3.72) | 0.006 |
| 50-200 | 74 (37.95) | 410 (24.09) | 3.31 (2.01-5.45) | 0.001 |
| <50 | 54 (27.69) | 256 (15.04) | 4.57 (2.69-7.76) | 0.001 |
| Trend test for strata of CD4 count | 241 (100.00) | 2,147 (100.00) | 1.70 (1.45-1.99) | 0.001 |
HIV, human immunodeficiency virus; TB, tuberculosis; CI, confidence interval.
HIV+/TB+, human immunodeficiency virus positive patients with Mycobacterium tuberculosis co-infection;
HIV+/TB-, human immunodeficiency virus positive patients without Mycobacterium tuberculosis co-infection.